Isoxazolines as inhibitors of fatty acid amide hydrolase

A compound of formula (I):

• or a pharmaceutically acceptable form thereof,
• wherein:
• Ra and Rd are joined to form a C3-10 carbocycyl or 3-14 membered heterocyclyl fused ring, and Rb and Rc are independently selected from —H, C1-10 alkyl and C1-10 perhaloalkyl;
• or
• (ii) Rc and Rd are joined to form a C3-10 carbocycyl or 3-14 membered heterocyclyl spiro-fused ring, and Ra and Rb are independently selected from —H, C1-10 alkyl and C1-10 perhaloalkyl;
• L is a covalent bond or a divalent C1-6 hydrocarbon group, wherein one, two or three methylene units of L are optionally and independently replaced with one or more oxygen, sulfur or nitrogen atoms;
• G is selected from —CN, —NO2, —S(═O)Re, —SO2Re, —SO2NRfRe, —PO2Re, —PO2ORe, —PO2NRfRe, —(C═O )Re, —(C═O )ORe, —(C═O )NRfRe, —Br, —I, —F, —Cl, —ORe, —ONRfRe, —ONRf(C═O)Re, —ONRfSO2Re, —ONRfPO2Re, —ONRfPO2ORe, —SRe, —OSO2Re, —NRfSO2Re, —OPO2Re, —OPO2ORe, —NRfPO2Re, —NRfPO2ORe, —OPO2NRfRe, —O(C═O)Re, —O(C═O)ORe, —NRfRe, —NRf(C═O)Re, —NRf(C═O)ORe, —O(C═O)NRfRe, —NRf(C═NRf)NRfRe, —O(C═NRf)NRfRe, —NRf(C═NRf)ORe, —[N(Rf)2Re]+X− wherein X− is a counterion;
• and
• each Re is selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocycyl, C6-14 aryl, 3-14 membered heterocyclyl and 5-14 membered heteroaryl;
• each Rf attached to a nitrogen atom is, independently, selected from —H, C1-10 alkyl, or an amino protecting group;
• or Re and Rf are joined to form an 3-14 membered heterocyclyl ring or an 5-14 membered heteroaryl ring.